Chemogenomic Screening in a Patient‐Derived 3D Fatty Liver Disease Model Reveals the CHRM1‐TRPM8 Axis as a Novel Module for Targeted Intervention

Chemogenomic Screening in a Patient‐Derived 3D Fatty Liver Disease Model Reveals the CHRM1‐TRPM8 Axis as a Novel Module for Targeted Intervention

Abstract Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of chronic liver disease with few therapeutic options. To narrow the translational gap in the development of pharmacological MASH treatments, a 3D liver model from primary human hepatocytes and non‐parenchymal cells...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonia Youhanna, Aurino M. Kemas, Shane C. Wright, Yi Zhong, Britta Klumpp, Kathrin Klein, Aikaterini Motso, Maurice Michel, Nicole Ziegler, Mingmei Shang, Pierre Sabatier, Aimo Kannt, Hongda Sheng, Nuria Oliva‐Vilarnau, Florian A. Büttner, Brinton Seashore‐Ludlow, Jonas Schreiner, Maike Windbergs, Martin Cornillet, Niklas K. Björkström, Andreas J. Hülsmeier, Thorsten Hornemann, Jesper V. Olsen, Yi Wang, Roberto Gramignoli, Michael Sundström, Volker M. Lauschke
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Advanced Science
Subjects:
chemical probes
fibrosis
muscarinic receptor
NASH
phenotypic assay
target discovery
Online Access:https://doi.org/10.1002/advs.202407572
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202407572

Similar Items